Key Takeaway: CONSHOHOCKEN, Pa., May 11, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), announced today its management team will participate in a fireside ch
Price reaction · baseline $292.15 (2023-05-10 close) · hit after-hours · clean, no other MDGL news in the window
day 0 close · peak
-1.4%
Market Sentiment Analysis
POSITIVE FACTORS
Madrigal Pharmaceuticals is engaging in a key industry event, enhancing visibility.
The management team's participation in a fireside chat indicates confidence and preparedness.
The focus on novel therapeutics for NASH addresses a significant medical need.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+125%
120-day peak, hindsight
Typical move
4.2%
average across 7 past catalysts
Cash runway
~45 mo
Minimal dilution risk
Lead asset
Resmetirom
Phase 3 · Non-Alcoholic Fatty Liver Disease
Full Press Release Details
CONSHOHOCKEN, Pa., May 11, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), announced today its management team will participate in a fireside chat at the
The JMP Securities Life Sciences Conference on Tuesday, May 16, 2023 at 10:30 am ET.
The fireside chat will be webcast and an archived recording will be available for replay in the Investors section of the Madrigal website after the event.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a once daily, oral, thyroid hormone receptor (THR)-β selective agonist designed to target key underlying causes of NASH in the liver. For more information, visit www.madrigalpharma.com.
Frequently Asked Questions
What is Madrigal Pharmaceuticals focused on?
Madrigal Pharmaceuticals specializes in developing treatments for nonalcoholic steatohepatitis (NASH).
When is Madrigal's fireside chat scheduled?
The fireside chat is set for May 16, 2023, at 10:30 am ET.
How can I watch the fireside chat?
The chat will be webcast live and available for replay on Madrigal's website.
What is the lead candidate of Madrigal Pharmaceuticals?
Madrigal's lead candidate is resmetirom, a thyroid hormone receptor selective agonist.
Where can I find more information about Madrigal?
More details are available on Madrigal Pharmaceuticals' official website.